No Data
No Data
IceCure's ProSense Cryoablation Safe and Effective in Destruction of Kidney Tumors With 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results
Icecure Medical Analyst Ratings
IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript Summary
IceCure Medical Price Target Raised to $4.60 From $4.16 at Brookline
IceCure Medical GAAP EPS of $0.22 , Revenue of $2.41M
Icecure Medical | 6-K: Report of foreign private issuer (related to financial reporting)
No Data